These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 9850031

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A phase I dose escalation and pharmacodynamic study of SU5416 (semaxanib) combined with weekly cisplatin and irinotecan in patients with advanced solid tumors.
    Martin LK, Bekaii-Saab T, Serna D, Monk P, Clinton SK, Grever MR, Kraut EH.
    Onkologie; 2013; 36(11):657-60. PubMed ID: 24192770
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients.
    Falcone A, Di Paolo A, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Del Tacca M, Conte P.
    J Clin Oncol; 2001 Aug 01; 19(15):3456-62. PubMed ID: 11481350
    [Abstract] [Full Text] [Related]

  • 25. Phase I trial of escalating-dose irinotecan given weekly with cisplatin and concurrent radiotherapy in locally advanced esophageal cancer.
    Ilson DH, Bains M, Kelsen DP, O'Reilly E, Karpeh M, Coit D, Rusch V, Gonen M, Wilson K, Minsky BD.
    J Clin Oncol; 2003 Aug 01; 21(15):2926-32. PubMed ID: 12885811
    [Abstract] [Full Text] [Related]

  • 26. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC, Adjei AA, Reid JM, Sloan JA, Atherton PJ, Rubin J, Alberts SR, Duncan BA, Denis L, Schaaf LJ, Yin D, Sharma A, McGovren P, Miller LL, Erlichman C.
    Cancer Chemother Pharmacol; 2006 Aug 01; 58(2):165-72. PubMed ID: 16328416
    [Abstract] [Full Text] [Related]

  • 27. Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer.
    Kobayashi K, Shinbara A, Kamimura M, Takeda Y, Kudo K, Kabe J, Hibino S, Hino M, Shibuya M, Kudoh S.
    Cancer Chemother Pharmacol; 1998 Aug 01; 42(1):53-8. PubMed ID: 9619758
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients.
    Abigerges D, Chabot GG, Armand JP, Hérait P, Gouyette A, Gandia D.
    J Clin Oncol; 1995 Jan 01; 13(1):210-21. PubMed ID: 7799022
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Phase I clinical and pharmacokinetic trial of docetaxel and irinotecan administered on a weekly schedule.
    Garcia AA, Pujari M, Jeffers S, Iqbal S, Lenz HJ, Beringer P, Louie S.
    Cancer Chemother Pharmacol; 2005 Jul 01; 56(1):75-82. PubMed ID: 15809878
    [Abstract] [Full Text] [Related]

  • 36. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer.
    Ilson DH.
    Oncology (Williston Park); 2004 Dec 01; 18(14 Suppl 14):22-5. PubMed ID: 15685830
    [Abstract] [Full Text] [Related]

  • 37. Irinotecan in combination with thalidomide in patients with advanced solid tumors: a clinical study with pharmacodynamic and pharmacokinetic evaluation.
    Allegrini G, Di Paolo A, Cerri E, Cupini S, Amatori F, Masi G, Danesi R, Marcucci L, Bocci G, Del Tacca M, Falcone A.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):585-93. PubMed ID: 16680463
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil.
    Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF, Creaven PJ, Noel DC, Iyer RV, Rustum YM.
    Clin Cancer Res; 2007 Feb 01; 13(3):965-71. PubMed ID: 17289892
    [Abstract] [Full Text] [Related]

  • 40. A phase I, dose-finding study of irinotecan (CPT-11) short i.v. infusion combined with fixed dose of 5-fluorouracil (5-FU) protracted i.v. infusion in adult patients with advanced solid tumours.
    Sastre J, Paz-Ares L, Carcas A, Alfonso R, Grávalos C, Frías J, Guerra P, Pronk L, Cortés-Funes H, Díaz-Rubio E.
    Cancer Chemother Pharmacol; 2005 May 01; 55(5):453-60. PubMed ID: 15818508
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.